Loading...
Foghorn Therapeutics Inc.
FHTX•NASDAQ
HealthcareBiotechnology
$4.46
$0.34(8.25%)
Foghorn Therapeutics Inc. (FHTX) Financial Performance & Statements
Review Foghorn Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-33.83%
↓ 33.83%
Operating Income Growth
4.84%
↑ 4.84%
Net Income Growth
11.99%
↑ 11.99%
Operating Cash Flow Growth
14.99%
↑ 14.99%
Operating Margin
-414.41%
↓ 414.41%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-342.23%
↓ 342.23%
ROE
214.80%
↑ 214.80%
ROIC
-51.98%
↓ 51.98%
Foghorn Therapeutics Inc. (FHTX) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Foghorn Therapeutics Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.86M | $7.81M | $6.89M | $5.05M |
| Cost of Revenue | $0.00 | $700000.00 | $800000.00 | $835000.00 |
| Gross Profit | $2.86M | $7.11M | $6.09M | $4.21M |
| Gross Profit Ratio | $1.00 | $0.91 | $0.88 | $0.83 |
| R&D Expenses | $20.51M | $24.69M | $23.00M | $24.70M |
| SG&A Expenses | $6.35M | $6.97M | $7.33M | $7.71M |
| Operating Expenses | $26.86M | $31.66M | $30.32M | $32.41M |
| Total Costs & Expenses | $26.86M | $31.66M | $31.12M | $33.24M |
| Interest Income | $3.10M | $3.50M | $2.87M | $2.44M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $761000.00 | $0.00 | $800000.00 | $835000.00 |
| EBITDA | -$23.24M | -$23.85M | -$23.44M | -$27.36M |
| EBITDA Ratio | -$8.14 | -$3.05 | -$3.40 | -$5.42 |
| Operating Income | -$24.005M | -$23.85M | -$24.23M | -$28.19M |
| Operating Income Ratio | -$8.41 | -$3.05 | -$3.52 | -$5.58 |
| Other Income/Expenses (Net) | $4.50M | $4.73M | $3.65M | $3.18M |
| Income Before Tax | -$19.50M | -$19.12M | -$22.98M | -$25.02M |
| Income Before Tax Ratio | -$6.83 | -$2.45 | -$3.34 | -$4.95 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $791724.00 |
| Net Income | -$19.50M | -$19.12M | -$22.98M | -$25.02M |
| Net Income Ratio | -$6.83 | -$2.45 | -$3.34 | -$4.95 |
| EPS | -$0.31 | -$0.31 | -$0.45 | -$0.59 |
| Diluted EPS | -$0.31 | -$0.31 | -$0.45 | -$0.59 |
| Weighted Avg Shares Outstanding | $62.60M | $62.60M | $51.58M | $42.43M |
| Weighted Avg Shares Outstanding (Diluted) | $62.60M | $62.60M | $51.58M | $42.43M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan